Literature DB >> 10146965

The economic costs of asthma: a review and conceptual model.

K B Weiss1, S D Sullivan.   

Abstract

There is a growing international concern about increasing asthma morbidity. While much is known about asthma morbidity, there are few available data on the economic burden of this condition, particularly in underdeveloped countries. In the absence of data on social costs, it is not possible to develop rational approaches to policies regarding resource allocation to reduce morbidity. The purpose of this article is to provide a review of the available literature on the social costs of illness for asthma. In light of this literature, we propose a conceptual model that links asthma morbidity to the social opportunity costs of the disease. We then delineate a framework, based on the proposed model, that can be used to conceptualise and evaluate the relative impact of alternative asthma intervention strategies. Based upon proposed analyses using this model, we believe that it would be possible to compare how various intervention strategies are likely to affect asthma costs and morbidity, thus providing a means for a more rational approach to healthcare policies regarding societal resource allocation for asthma.

Entities:  

Mesh:

Year:  1993        PMID: 10146965     DOI: 10.2165/00019053-199304010-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  39 in total

1.  An economic evaluation of asthma in the United States.

Authors:  K B Weiss; P J Gergen; T A Hodgson
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

2.  The cost of migraine: more than just a headache?

Authors:  P J Davey; S R Leeder
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

Review 3.  Measurement of health status in the 1990s.

Authors:  D L Patrick; M Bergner
Journal:  Annu Rev Public Health       Date:  1990       Impact factor: 21.981

4.  Direct and indirect costs associated with the management of childhood asthma.

Authors:  R J Marion; T L Creer; R V Reynolds
Journal:  Ann Allergy       Date:  1985-01

5.  Cost-of-illness methodology: a guide to current practices and procedures.

Authors:  T A Hodgson; M R Meiners
Journal:  Milbank Mem Fund Q Health Soc       Date:  1982

6.  Increasing prevalence of asthma in children.

Authors:  E A Mitchell
Journal:  N Z Med J       Date:  1983-06-22

7.  Geographic variations in US asthma mortality: small-area analyses of excess mortality, 1981-1985.

Authors:  K B Weiss; D K Wagener
Journal:  Am J Epidemiol       Date:  1990-07       Impact factor: 4.897

8.  International trends in asthma mortality: 1970 to 1985.

Authors:  R Jackson; M R Sears; R Beaglehole; H H Rea
Journal:  Chest       Date:  1988-11       Impact factor: 9.410

9.  Variations in asthma hospitalizations and deaths in New York City.

Authors:  W Carr; L Zeitel; K Weiss
Journal:  Am J Public Health       Date:  1992-01       Impact factor: 9.308

10.  National trends in the morbidity and mortality of asthma in the US. Prevalence, hospitalization and death from asthma over two decades: 1965-1984.

Authors:  R Evans; D I Mullally; R W Wilson; P J Gergen; H M Rosenberg; J S Grauman; F M Chevarley; M Feinleib
Journal:  Chest       Date:  1987-06       Impact factor: 9.410

View more
  16 in total

1.  Factors associated with hospital admissions and repeat emergency department visits for adults with asthma.

Authors:  R J Adams; B J Smith; R E Ruffin
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

2.  Quality-of-life outcomes and the use of antihistamines in a French national population-based sample of patients with perennial rhinitis.

Authors:  P D Pariente; C LePen; F Los; J Bousquet
Journal:  Pharmacoeconomics       Date:  1997-11       Impact factor: 4.981

3.  Issues in conducting randomized controlled trials of health services research interventions in nonacademic practice settings: the case of retail pharmacies.

Authors:  Morris Weinberger; Michael D Murray; David G Marrero; Nancy Brewer; Michael Lykens; Lisa E Harris; A Jeffrey Newell; Joyce Collins; William M Tierney
Journal:  Health Serv Res       Date:  2002-08       Impact factor: 3.402

4.  The active patient role and asthma outcomes in an underserved rural community.

Authors:  Henry N Young; Tonja L Larson; Elizabeth D Cox; Megan A Moreno; Joshua M Thorpe; Neil J MacKinnon
Journal:  J Rural Health       Date:  2013-06-11       Impact factor: 4.333

5.  Understanding the costs of asthma: the next step.

Authors:  K B Weiss; S D Sullivan
Journal:  CMAJ       Date:  1996-03-15       Impact factor: 8.262

6.  Utilization, spending, and price trends for short- and long-acting Beta-agonists and inhaled corticosteroids in the medicaid program, 1991-2010.

Authors:  Shih-Feng Chiu; Christina M L Kelton; Jeff Jianfei Guo; Patricia R Wigle; Alex C Lin; Sheryl L Szeinbach
Journal:  Am Health Drug Benefits       Date:  2011-05

7.  Characterisation of asthma management in the Fallon Community Health Plan from 1988 to 1991.

Authors:  S F Lanes; B M Birmann; A M Walker; A L Sheffer; R A Rosiello; B E Lewis; N A Dreyer
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

Review 8.  Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma.

Authors:  D H Peters; D Faulds
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

9.  Asthma management by medical practitioners: the situation in a developing country.

Authors:  Osarogiagbon Wilson Osaretin; Nwaneri Damian Uchechukwu; Oviawe Osawaru
Journal:  World J Pediatr       Date:  2012-12-29       Impact factor: 2.764

10.  Patient And phaRmacist Telephonic Encounters (PARTE) in an underserved rural population with asthma: methods and rationale.

Authors:  Henry N Young; S Nadra Havican; Betty A Chewning; Christine A Sorkness; Xin Ruppel; Sara Griesbach
Journal:  Innov Pharm       Date:  2011-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.